Hobbs Group Advisors’s Pfizer PFE Stock Holding History

Hobbs Group Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,699	Closed	-$339K	–	477
2024 Q3	$339K	Sell	11,699 -16,353	-58%	-$477K	0.12%	108
2024 Q2	$785K	Buy	+28,052	New	+$772K	0.3%	59
2023 Q4	$458K	Buy	+15,899	New	+$481K	0.2%	77

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hobbs Group Advisors's PFE Position: Q4 2024 in Review

Hobbs Group Advisors sold out of Pfizer (PFE) in Q4 2024, closing a stake of 11,699 shares — an estimated $339K sold.

Hobbs Group Advisors first reported a position in PFE in Q4 2023 and held it in 3 quarters. The position peaked at $785K in Q2 2024. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Hobbs Group Advisors reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Hobbs Group Advisors sold 11,699 Pfizer shares in Q4 2024, an estimated $339K.
Hobbs Group Advisors first reported a position in Pfizer in Q4 2023 and held it in 3 quarters.
Hobbs Group Advisors's Pfizer position peaked at $785K in Q2 2024.
2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Hobbs Group Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.